Search

Your search keyword '"Doan, Serge"' showing total 276 results
Start Over Author "Doan, Serge"
276 results on '"Doan, Serge"'

8. Lichen planus pemphigoides with predominant mucous membrane involvement: a series of 12 patients and a literature review

Author

Combemale, Loraine, primary, Bohelay, Gérôme, additional, Sitbon, Ishaï-Yaacov, additional, Ahouach, Btisseme, additional, Alexandre, Marina, additional, Martin, Antoine, additional, Pascal, Francis, additional, Soued, Isaac, additional, Doan, Serge, additional, Morin, Florence, additional, Grootenboer-Mignot, Sabine, additional, Caux, Frédéric, additional, Prost-Squarcioni, Catherine, additional, and Le Roux-Villet, Christelle, additional

Published
2024
Full Text
View/download PDF

9. Lichen planus pemphigoides with predominant mucous membrane involvement: a series of 12 patients and a literature review

Author

Combemale, Loraine, Bohelay, Gérôme, Sitbon, Ishaï Yaacov, Ahouach, Btisseme, Alexandre, Marina, Martin, Antoine, Pascal, Francis, Soued, Isaac, Doan, Serge, Morin, Florence, Grootenboer-Mignot, Sabine, Caux, Frédéric, Prost-Squarcioni, Catherine, Le Roux-Villet, Christelle, Combemale, Loraine, Bohelay, Gérôme, Sitbon, Ishaï Yaacov, Ahouach, Btisseme, Alexandre, Marina, Martin, Antoine, Pascal, Francis, Soued, Isaac, Doan, Serge, Morin, Florence, Grootenboer-Mignot, Sabine, Caux, Frédéric, Prost-Squarcioni, Catherine, and Le Roux-Villet, Christelle

Abstract

Background: Lichen planus pemphigoides (LPP), an association between lichen planus and bullous pemphigoid lesions, is a rare subepithelial autoimmune bullous disease. Mucous membrane involvement has been reported previously; however, it has never been specifically studied. Methods: We report on 12 cases of LPP with predominant or exclusive mucous membrane involvement. The diagnosis of LPP was based on the presence of lichenoid infiltrates in histology and immune deposits in the basement membrane zone in direct immunofluorescence and/or immunoelectron microscopy. Our systematic review of the literature, performed according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines, highlights the clinical and immunological characteristics of LPP, with or without mucous membrane involvement. Results: Corticosteroids are the most frequently used treatment, with better outcomes in LPP with skin involvement alone than in that with mucous membrane involvement. Our results suggest that immunomodulators represent an alternative first-line treatment for patients with predominant mucous membrane involvement., SCOPUS: ar.j, info:eu-repo/semantics/published

Published
2024

10. TFOS European Ambassador meeting: Unmet needs and future scientific and clinical solutions for ocular surface diseases

Author

Erickson, Susan, Sullivan, Amy Gallant, Barabino, Stefano, Begovic, Enesa, Benitez-del-Castillo, Jose M., Bonini, Stefano, Borges, José Salgado, Brzheskiy, Vladimir, Bulat, Nina, Cerim, Alma, Craig, Jennifer P., Cușnir, Valeriu, Cușnir, Valeriu, Jr., Cușnir, Vitalie, Doan, Serge, Dülger, Erol, Farrant, Sarah, Geerling, Gerd, Goldblum, David, Golubev, Sergey, Gomes, José A.P., González- Méijome, José Manuel, Grupcheva, Christina N., Gündüz, Ömür Uçakhan, Horwath-Winter, Jutta, Källmark, Fredrik, Karanadze, Nino, Karcic, Huda Hajjir, Karcic, Suvad, Kontadakis, Georgios, Messmer, Elisabeth M., Mrugacz, Malgorzata, Murphy, Conor, O'Leary, Olivia E., Procopciuc, Vitalie, Pult, Heiko, Raus, Peter, Şahin, Afsun, Setälä, Niko, Stanila, Adriana, Stanila, Dan Mircea, Utheim, Tor Paaske, Vehof, Jelle, Versura, Piera, Villani, Edoardo, Willcox, Mark D.P., Wolffsohn, James S., Zagórski, Zbigniew, Zoega, Gunnar Már, and Sullivan, David A.

Published
2020
Full Text
View/download PDF

15. Anti‐interleukin 5 for treating severe refractory vernal keratoconjunctivitis in children: Two cases.

Author

Wanin, Stéphanie, Mercier, Marie, Elaouane, Imane, Chelly, Zied, Bourgoin‐Heck, Mélisande, Lambert, Nathalie, and Doan, Serge

Subjects
ALLERGIC conjunctivitis, KERATOCONJUNCTIVITIS, RESPIRATORY diseases, REFRACTORY materials, T helper cells
Abstract

This article explores the use of anti-IL5 therapy as a potential treatment option for severe refractory vernal keratoconjunctivitis (VKC) in children. VKC is a chronic inflammatory disease that primarily affects children and is often associated with other allergic conditions. The article presents two cases where children with severe VKC were successfully switched to anti-IL5 therapy after previous treatment failures. While the therapy showed some improvement in symptoms and inflammation, topical corticosteroids were still necessary. The article suggests that further research and clinical trials are needed to confirm the efficacy of anti-IL5 therapy for refractory VKC, and emphasizes the importance of personalized treatment approaches based on individual patient profiles. [Extracted from the article]

Published
2024
Full Text
View/download PDF

16. Risk factors for severe hearing loss in Susac syndrome: A national cohort study.

Author

Peyre, Marion, Mageau, Arthur, Henry Feugeas, Marie‐Cécile, Doan, Serge, Halimi, Caroline, Klein, Isabelle, Goulenok, Tiphaine, François, Chrystelle, Chauveheid, Marie‐Paule, Papo, Thomas, Sacré, Karim, Alexandra, Jean‐Francois, Aumaitre, Olivier, Beldjoudi, Naima, Bodenant, Marie, Capron, Jean, de Brouker, Thomas, de Bustos, Elisabeth Medeiros, Debruxelles, Sabrina, and Delory, Nicole

Subjects
HEARING disorders, CONDUCTIVE hearing loss, MAGNETIC resonance imaging, COHORT analysis, HEARING aids, AUDIOMETRY
Abstract

Background: Nonreversible hearing loss (HL) is the main sequelae of Susac syndrome (SuS). We aimed to identify risk factors for HL in SuS. Methods: The CARESS study is a prospective national cohort study that started in December 2011, including all consecutive patients with SuS referred to the French reference center. The CARESS study was designed with a follow‐up including fundoscopy, audiometry, and brain magnetic resonance imaging at 1, 3, 6, and 12 months after diagnosis and then annually for 5 years. The primary outcome was the occurrence at last follow‐up of severe HL defined as the loss of 70 dB in at least one ear on audiometry or the need for hearing aids. Results: Thirty‐six patients (female 66.7%, median age 37.5 [range 24.5–42.5] years) included in the clinical study were analyzed for the primary outcome. Thirty‐three patients (91.7%) had cochleovestibular involvement at SuS diagnosis including HL >20 dB in at least one ear in 25 cases. At diagnosis, 32 (88.9%), 11 (30.6%), and 7 (19.4%) patients had received steroids, intravenous immunoglobulin, and/or immunosuppressive (IS) drugs, respectively. After a median follow‐up of 51.8 [range 29.2–77.6] months, 19 patients (52.8%) experienced severe HL that occurred a median of 13 [range 1.5–29.5] months after diagnosis. Multivariable analysis showed that the odds of severe HL were lower in patients who received IS drugs at diagnosis (OR 0.15, 95% CI 0.01–1.07, p = 0.058). Conclusions: Severe HL in SuS is associated with the absence of IS drugs given at diagnosis. Our findings support the systematic use of IS drugs in SuS. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

17. Definition and Diagnostic Criteria for Pediatric Blepharokeratoconjunctivitis

Author

Morales-Mancillas, Nallely R., primary, Velazquez-Valenzuela, Fabiola, additional, Kinoshita, Shigeru, additional, Suzuki, Tomo, additional, Dahlmann-Noor, Annegret H., additional, Dart, John K. G., additional, Hingorani, Melanie, additional, Ali, Asim, additional, Fung, Simon, additional, Akova, Yonca A., additional, Doan, Serge, additional, Gupta, Noopur, additional, Hammersmith, Kristin M., additional, Tan, Donald T. H., additional, Paez-Garza, J. Homar, additional, and Rodriguez-Garcia, Alejandro, additional

Published
2023
Full Text
View/download PDF

29. Rituximab Therapy for Mucous Membrane Pemphigoid: A Retrospective Monocentric Study With Long-Term Follow-Up in 109 Patients

Author

Bohelay, Gérôme, primary, Alexandre, Marina, additional, Le Roux-Villet, Christelle, additional, Sitbon, Ishaï, additional, Doan, Serge, additional, Soued, Isaac, additional, Shourick, Jason, additional, Rousset, Laurie, additional, Mellottee, Benoît, additional, Heller, Michel, additional, Lièvre, Nicole, additional, Zumelzu, Coralie, additional, Morin, Florence, additional, Grootenboer-Mignot, Sabine, additional, Gabison, Eric, additional, Caux, Frédéric, additional, Prost-Squarcioni, Catherine, additional, and Musette, Philippe, additional

Published
2022
Full Text
View/download PDF

32. EAACI position paper on the clinical use of the bronchial allergen challenge: Unmet needs and research priorities

Author

Agache, Ioana, primary, Antolin‐Amerigo, Dario, additional, Blay, Frederic, additional, Boccabella, Cristina, additional, Caruso, Cristiano, additional, Chanez, Pascal, additional, Couto, Mariana, additional, Covar, Ronina, additional, Doan, Serge, additional, Fauquert, Jean‐Luc, additional, Gauvreau, Gail, additional, Gherasim, Alina, additional, Klimek, Ludger, additional, Lemiere, Catherine, additional, Nair, Parameswaran, additional, Ojanguren, Iñigo, additional, Peden, David, additional, Perez‐de‐Llano, Luis, additional, Pfaar, Oliver, additional, Rondon, Carmen, additional, Rukhazde, Maia, additional, Sastre, Joaquin, additional, Schulze, Johannes, additional, Silva, Diana, additional, Tarlo, Susan, additional, Toppila‐Salmi, Sanna, additional, Walusiak‐Skorupa, Jolanta, additional, Zielen, Stefan, additional, and Eguiluz‐Gracia, Ibon, additional

Published
2022
Full Text
View/download PDF

34. Pemphigoïdes des muqueuses traitées par rituximab : étude rétrospective monocentrique chez 109 patients avec suivi à long terme

Author

Alexandre, Marina, primary, Bohelay, Gérôme, additional, Le Roux-Villet, Christelle, additional, Doan, Serge, additional, Soued, Isaac, additional, Rousset, Laurie, additional, Sitbon, Ishaï, additional, Mellottee, Benoït, additional, Heller, Michel, additional, Lièvre, Nicole, additional, Caux, Frédéric, additional, Prost, Catherine, additional, and Musette, Philippe, additional

Published
2021
Full Text
View/download PDF

36. Definitions and outcome measures for mucous membrane pemphigoid: Recommendations of an international panel of experts

Author

Murrell, Dedee F., Marinovic, Branka, Caux, Frederic, Prost, Catherine, Ahmed, Razzaque, Wozniak, Katarzyna, Amagai, Masayuki, Bauer, Johann, Beissert, Stefan, Borradori, Luca, Culton, Donna, Fairley, Janet A., Fivenson, David, Jonkman, Marcel F., Marinkovich, Peter M., Woodley, David, Zone, John, Aoki, Valeria, Bernard, Philippe, Bruckner-Tuderman, Leena, Cianchini, Giuseppe, Venning, Vanessa, Diaz, Luis, Eming, Rudiger, Grando, Sergei A., Hall, Russell P., Hashimoto, Takashi, Herrero-González, Josep E., Hertl, Michael, Joly, Pascal, Karpati, Sarolta, Kim, Jaehwan, Kim, Soo Chan, Korman, Neil J., Kowalewski, Cezary, Lee, Sang Eun, Rubenstein, David R., Sprecher, Eli, Yancey, Kim, Zambruno, Giovanna, Zillikens, Detlef, Doan, Serge, Daniel, Benjamin S., and Werth, Victoria P.

Published
2015
Full Text
View/download PDF

41. TFOS European ambassador meeting:Unmet needs and future scientific and clinical solutions for ocular surface diseases

Author

Erickson, Susan, Sullivan, Amy Gallant, Barabino, Stefano, Begovic, Enesa, Benitez-Del-Castillo, Jose M, Bonini, Stefano, Borges, José Salgado, Brzheskiy, Vladimir, Bulat, Nina, Cerim, Alma, Craig, P, Cușnir, Valeriu, Cușnir, Vitalie, Doan, Serge, Dülger, Erol, Farrant, Sarah, Geerling, Gerd, Goldblum, David, Golubev, Sergey, Gomes, José A P, González-Méijome, José Manuel, Grupcheva, Christina N, Gündüz, Ömür Uçakhan, Horwath-Winter, Jutta, Källmark, Fredrik, Karanadze, Nino, Karcic, Huda Hajjir, Karcic, Suvad, Kontadakis, Georgios, Messmer, Elisabeth M, Mrugacz, Malgorzata, Murphy, Conor, O'Leary, Olivia E, Procopciuc, Vitalie, Pult, Heiko, Raus, Peter, Şahin, Afsun, Setälä, Niko, Stanila, Adriana, Stanila, Dan Mircea, Utheim, Tor Paaske, Vehof, Jelle, Versura, Piera, Villani, Edoardo, Willcox, Mark D P, Wolffsohn, James S, Zagórski, Zbigniew, Zoega, Gunnar Már, and Sullivan, David A

Abstract

The mission of the Tear Film & Ocular Surface Society (TFOS) is to advance the research, literacy, and educational aspects of the scientific field of the tear film and ocular surface. Fundamental to fulfilling this mission is the TFOS Global Ambassador program. TFOS Ambassadors are dynamic and proactive experts, who help promote TFOS initiatives, such as presenting the conclusions and recommendations of the recent TFOS DEWS II™, throughout the world. They also identify unmet needs, and propose future clinical and scientific solutions, for management of ocular surface diseases in their countries. This meeting report addresses such needs and solutions for 25 European countries, as detailed in the TFOS European Ambassador meeting in Rome, Italy, in September 2019.

Published
2020

42. TFOS European Ambassador meeting: unmet needs and future scientific and clinical solutions for ocular surface diseases

Author

Şahin, Afsun (ORCID 0000-0002-5083-5618 & YÖK ID 171267), Erickson, Susan; Sullivan, Ammy Gallant; Barabino, Stefano; Begovic, Enesa; Benitez-del-Castillo Jose M.; Bonini Stefano; Borges Jose Salgado; Brzheskiy, Vlademir; Bulat, Nina; Cerim, Alma; Craig, Jennifer P.; Cușnir, Valeriu Jr.; Cusnir, Valeriu; Cusnir, Vitalie; Doan Serge; Dülger, Erol; Farrant, Sarah; Geerling, Gerd; Goldblum, David; Golubev, Sergey; Gomes, Jose A.P.; González-Méijome, Jose Manuel; Grupcheva, Christina N.; Gündüz, Ömür Uçakhan; Horwath-Winter, Jutta; Källmark, Fredrik; Karanadze, Nino; Karcic, Huda Hajjir; Karcic, Suvad; Kontadakis, Georgious; Messmer, Elisabeth M.; Mrugacz, Malgorzata; Murphy, Conor; O'Leary, Olivia E.; Procopciuc, Vitalie; Pult, Heiko; Raus, Peter; Setälä, Niko; Stanila, Adrina; Stanila, Den Mircea; Utheim, Toor Paeske; Vehof, Jelle; Versura, Piera; Villani, Edoardo; Willcox, Mark D. P.; Wolffsohn, James S.; Zagórski, Zebigniew; Zoega, Gunnar Mar; Sullivan, David A., School of Medicine, Şahin, Afsun (ORCID 0000-0002-5083-5618 & YÖK ID 171267), Erickson, Susan; Sullivan, Ammy Gallant; Barabino, Stefano; Begovic, Enesa; Benitez-del-Castillo Jose M.; Bonini Stefano; Borges Jose Salgado; Brzheskiy, Vlademir; Bulat, Nina; Cerim, Alma; Craig, Jennifer P.; Cușnir, Valeriu Jr.; Cusnir, Valeriu; Cusnir, Vitalie; Doan Serge; Dülger, Erol; Farrant, Sarah; Geerling, Gerd; Goldblum, David; Golubev, Sergey; Gomes, Jose A.P.; González-Méijome, Jose Manuel; Grupcheva, Christina N.; Gündüz, Ömür Uçakhan; Horwath-Winter, Jutta; Källmark, Fredrik; Karanadze, Nino; Karcic, Huda Hajjir; Karcic, Suvad; Kontadakis, Georgious; Messmer, Elisabeth M.; Mrugacz, Malgorzata; Murphy, Conor; O'Leary, Olivia E.; Procopciuc, Vitalie; Pult, Heiko; Raus, Peter; Setälä, Niko; Stanila, Adrina; Stanila, Den Mircea; Utheim, Toor Paeske; Vehof, Jelle; Versura, Piera; Villani, Edoardo; Willcox, Mark D. P.; Wolffsohn, James S.; Zagórski, Zebigniew; Zoega, Gunnar Mar; Sullivan, David A., and School of Medicine

Abstract

The mission of the Tear Film & Ocular Surface Society (TFOS) is to advance the research, literacy, and educational aspects of the scientific field of the tear film and ocular surface. Fundamental to fulfilling this mission is the TFOS Global Ambassador program. TFOS Ambassadors are dynamic and proactive experts, who help promote TFOS initiatives, such as presenting the conclusions and recommendations of the recent TFOS DEWS II™, throughout the world. They also identify unmet needs, and propose future clinical and scientific solutions, for management of ocular surface diseases in their countries. This meeting report addresses such needs and solutions for 25 European countries, as detailed in the TFOS European Ambassador meeting in Rome, Italy, in September 2019., NA

Published
2020

49. Different Approach to Manage Demodex Blepharitis – Initial and Maintenance Treatment.

Author

Jacobi, Christina, Doan, Serge, Pavel, Viktoria, Chiambaretta, Frédéric, and Kärcher, Thomas

Subjects
*DEMODEX, *PATIENT satisfaction, *BLEPHARITIS, *TEA tree oil, *VISUAL acuity, *SYMPTOMS
Abstract

To evaluate the improvement of ocular signs and symptoms in patients suffering from Demodex blepharitis using a combined treatment approach: use of eyelid wipes impregnated with 2.5% terpinen-4-ol (T4O) and 0.2% hyaluronic acid (HA) in the initial treatment period and investigation of maintenance of the treatment effect with the use of eyelid cleansing wipes. Fifty patients with Demodex blepharitis were treated in the initial treatment period with sterile eyelid T4O impregnated wipes for 28 days. In the following four-week maintenance period, 82% patients received sterile eyelid maintenance wipes, while 16% continued treatment with T4O impregnated wipes. Global ocular discomfort, adapted TOSS, SANDE score, and individual blepharitis symptoms were assessed by patients at day 28 and day 56. Ocular signs were evaluated by the investigator at the study visits. Investigator's assessment of the overall treatment performance, patient's assessment of treatment satisfaction, and tolerability were evaluated with questionnaires. All global ocular discomfort symptoms and disease specific symptoms assessed by patients as well as all parameters evaluated by the investigators significantly improved in the initial treatment period with the application of eyelid wipes impregnated with 2.5% terpinen-4-ol until day 28. The therapeutic effect was maintained or even improved during the maintenance period under administration of mainly eyelid maintenance wipes until day 56. Both products were well tolerated. No adverse events and no clinically relevant changes in visual acuity were observed during both periods. Once daily treatment with T4O impregnated eyelid wipes in the initial treatment period significantly improved the ocular symptoms and signs and reduced the mite count in patients with Demodex blepharitis within four-weeks administration. Subsequent maintenance treatment with maintenance wipes for another 4 weeks preserved or further intensified the treatment success. The products were well tolerated and were convenient to use. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

50. Brain magnetic resonance imaging lesion load at diagnosis, severity at onset and outcomes in Susac syndrome: A prospective cohort study.

Author

Scheifer, Carole, Henry Feugeas, Marie‐Cécile, Roriz, Mélanie, Cohen Aubart, Fleur, Doan, Serge, Jouvent, Eric, Klein, Isabelle, Machado, Carla, Rouzaud, Diane, Papo, Thomas, and Sacré, Karim

Subjects
MAGNETIC resonance imaging, DIAGNOSIS, DIFFUSION magnetic resonance imaging, COHORT analysis, LONGITUDINAL method
Abstract

Background: Susac syndrome (SuS) is a rare occlusive microvessel disease of the brain, retina and inner ear. We aimed to determine whether brain lesion load at the acute phase predicts poor outcomes in SuS. Methods: A prospective national cohort study was conducted from December 2012 to December 2019 in 20 centres in France. Patients included at the principal investigator's center with available brain magnetic resonance imaging (MRI) at diagnosis were analyzed. MRI was reviewed by an experienced neuroradiologist blinded to clinical status. The size, topography and number of hyperintense lesions on diffusion‐weighted imaging (DWI‐HL) were analyzed at diagnosis and during follow‐up. Outcomes involved descriptive characteristics of patients at onset and last follow‐up. Results: Twenty‐three patients (38.1 [18.8–56.5] years, 16 females) were prospectively studied. The triad (i.e., brain, eye and ear involvement) was complete at onset in 17 patients. Brain MRI was performed 1.1 (0.1–3.4) months after the first symptom. All patients had DWI‐HL at the acute phase. Patients were separated into two groups according to the number of DWI‐HL on first MRI: a first group of patients (n=15) displaying low brain lesion load (<50 DWI‐HL per patient) and a second group of patients (n=8) displaying high brain lesion load (≥100 DWI‐HL). The median follow‐up was 57.9 (9.7–98) months. Clinical features, treatment, relapse rate, time to disappearance of DWI‐HL, disabilities and professional outcome did not differ according to brain lesion load. Conclusion: Brain lesion load assessed by DWI at the acute phase is not associated with risks of disability in SuS. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results